FDA Warning Letters to Online Peptide Sellers: What the Record Shows

This record covers FDA warning letters published from February 7, 2024 through August 24, 2026. It is a dated research snapshot, not a claim about actions published after that window. Warning letters state the agency's position about observed conduct and requested correction; they are not court judgments or automatic closure orders.

Within the review window, FDA published 15 letters to online research-peptide storefronts. Two additional March 2026 letters concerned consumer-format products listed on a marketplace and are discussed separately because they were not research-vial storefronts.

Storefront letters in the review window

The two marketplace letters were addressed to FormPour concerning a microneedle patch listing and Guangzhou Huli Technology Co., doing business as Fantasy Face concerning an oral solution listing. Keeping those entries separate preserves the difference between marketplace consumer products and the storefront population in the table.

Pattern 1: a disclaimer did not control intended use

Across the letters, FDA evaluated product descriptions and surrounding conduct rather than accepting a research-use disclaimer as dispositive. The governing concept appears in 21 CFR 201.128, which addresses objective intent through expressions and circumstances surrounding distribution.

This pattern is the central finding in the record. A label cannot be read separately from claims, instructions, linked content, and adjacent products.

Pattern 2: coded names were decoded

Several 2026 letters identified abbreviations and coded GLP names, then evaluated the products according to the substances FDA said those names represented. Renaming a substance did not remove the surrounding evidence. For research publishing, the lesson is straightforward: precise molecular names and status statements are more defensible than euphemisms.

Pattern 3: adjacent materials contributed context

Multiple letters discussed bacteriostatic water or reconstitution materials offered beside peptide listings. FDA treated the combination as evidence relevant to intended use. The agency was evaluating the system presented to the visitor, not only the wording on one page.

Pattern 4: linked communities and social accounts mattered

The Mile High Compounds letter cited a linked community containing detailed use information. Earlier letters also referenced social accounts that directed visitors to the storefront. Moving a claim to another channel did not remove it from the agency's analysis when the channels were connected.

Pattern 5: clinical outcomes used in commercial context mattered

Some letters quoted statements derived from human trials or disease endpoints. A peer-reviewed result can be scientifically sound in its original context while taking on a different regulatory meaning when placed beside an unapproved product listing. Citation alone does not determine intended use; placement and purpose matter.

How to use the warning-letter record

The FDA warning-letter search should be searched by legal entity, trade name, and domain. A later closeout letter, court filing, recall, or new agency action may change the public record. Absence from this dated table does not establish regulatory compliance, and presence does not prove every allegation in a separate legal proceeding.

The durable conclusion is about method: evaluate the complete publication and distribution context. Scientific education should identify evidence level, distinguish approved products from investigational compounds, avoid human-use instructions, and keep research reporting separate from commercial claims.